FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new compounds of formula (I) as (S)-stereoisomers or to their pharmaceutically acceptable salts which exhibit properties of MMP12 or MMP9 inhibitor. In formula (I) 
, R1 represents C1-2alkyl, cyclopropyl, OCH3 or SCH3, and said alkyl group is optionally substituted with one or more than one fluorine atom, and R2 represents C1-2alkyl.
EFFECT: invention also refers to methods for making compounds of formula (I), to the pharmaceutical composition and the method for making thereof, and also to application of the compounds of formula (I).
17 cl, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORS OF METALLOPROTEINASES, THEIR USING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2288228C2 |
| NEW DERIVATIVES OF HYDANTOIN AS INHIBITORS OF METAL PROTEINASES | 2005 |
|
RU2376301C2 |
| NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | 2005 |
|
RU2378269C2 |
| INHIBITORS OF METALLOPROTEINASES, THEIR USING AND PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF | 2002 |
|
RU2293730C2 |
| INHIBITORS OF METALLOPROTEINASES, THEIR USING AND PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF | 2002 |
|
RU2293729C2 |
| DERIVATIVES OF IMIDAZOLIDINE-2,4-DIONE, PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF AND THEIR USING | 2002 |
|
RU2285695C2 |
| HYDANTOIN DERIVATIVES, USEFUL AS METALLOPROTEINASE INHIBITORS | 2005 |
|
RU2388758C2 |
| HYDANTOIN DERIVATIVES USED AS MMP INHIBITORS | 2007 |
|
RU2463301C2 |
| QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
| AZASPIROALKANE DERIVATIVES METALLOPROTEASE INHIBITORS | 2004 |
|
RU2379303C2 |
